Orexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT Analysis Review

April 2017 | 52 pages | ID: OB08302671BEN
GlobalData

Abstracts

Orexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. The product is also sold in different countries worldwide through Orexigen’s partners. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. Orexigen is headquartered in La Jolla, California, the US.

Orexigen Therapeutics Inc Key Recent Developments

Mar 28,2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Nov 03,2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016
Aug 04,2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
Jun 22,2016: Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 27,2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Orexigen Therapeutics Inc - Key Facts
Orexigen Therapeutics Inc - Key Employees
Orexigen Therapeutics Inc - Key Employee Biographies
Orexigen Therapeutics Inc - Major Products and Services
Orexigen Therapeutics Inc - Pharmaceutical Pipeline Products Data
Orexigen Therapeutics Inc, Pipeline Products by Therapy Area
Orexigen Therapeutics Inc, Pipeline Products by Development Phase
Orexigen Therapeutics Inc - History
Orexigen Therapeutics Inc - Company Statement
Orexigen Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Orexigen Therapeutics Inc - Business Description
Orexigen Therapeutics Inc - Corporate Strategy
Orexigen Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Orexigen Therapeutics Inc - Strengths
Orexigen Therapeutics Inc - Weaknesses
Orexigen Therapeutics Inc - Opportunities
Orexigen Therapeutics Inc - Threats
Orexigen Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Orexigen Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
Jun 22, 2016: Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 27, 2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
Apr 25, 2016: Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees
Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Orexigen Therapeutics Inc, Key Facts
Orexigen Therapeutics Inc, Key Employees
Orexigen Therapeutics Inc, Key Employee Biographies
Orexigen Therapeutics Inc, Major Products and Services
Orexigen Therapeutics Inc, Number of Pipeline Products by Therapy Area
Orexigen Therapeutics Inc, Number of Pipeline Products by Development Stage
Orexigen Therapeutics Inc, History
Orexigen Therapeutics Inc, Subsidiaries
Orexigen Therapeutics Inc, Key Competitors
Orexigen Therapeutics Inc, Ratios based on current share price
Orexigen Therapeutics Inc, Annual Ratios
Orexigen Therapeutics Inc, Annual Ratios (Cont.1)
Orexigen Therapeutics Inc, Interim Ratios
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Orexigen Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Orexigen Therapeutics Inc, Pipeline Products by Therapy Area
Orexigen Therapeutics Inc, Pipeline Products by Development Phase
Orexigen Therapeutics Inc, Performance Chart (2012 - 2016)
Orexigen Therapeutics Inc, Ratio Charts
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Vivus Inc
Novo Nordisk A/S
GlaxoSmithKline Plc
Genentech Inc
Eisai Inc
Arena Pharmaceuticals Inc